Myopericarditis with Hemorrhagic Pericardial Effusion Following BNT162b2 mRNA COVID-19 Vaccine
8 Pages Posted: 22 Mar 2022
Abstract
Since the start of the pandemic, to date, around 200 million cases have been diagnosed with COVID-19 worldwide with an estimated 4.2 million death toll. Mass vaccination has taken place to control the spread of infection with the most commonly used vaccines being Pfizer-BioNTech and Moderna. However, the adverse events associated with vaccination have not been fully investigated. Of concern are some serious cardiovascular events such as myocarditis, pericarditis or perimyocarditis development post-vaccination. Hemorrhagic pericardial effusion has not been reported. We report a case of myopericarditis with a hemorrhagic pericardial effusion that developed two weeks following BNT162b2 mRNA COVID-19 vaccine. We performed a complete workup for the underlying cause without any significant findings. Our patient was treated with colchicine with ibuprofen, and he made full recovery. A follow-up cardiovascular magnetic resonance imaging (CMR) showed no signs of active inflammation.
Note:
Funding: None to declare.
Declaration of Interests: The authors report no conflicts of interest.
Patient Informed Consent Statement: The patient gave permission for this case to be published. The design of the work has been approved by the Mercyhealth Offices of Research Administration and Privacy.
Keywords: COVID-19, COVID-19 vaccine, myopericarditis, pericardial effusion, hemorrhagic pericardial effusion
Suggested Citation: Suggested Citation